Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TETRACYCLINE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (J01AA) — coverage varies; not interchangeable

  • Doxycycline hyclate (PMS-Doxycycline): general benefit, Not a benefit
  • Minocycline (Minocycline): general benefit, Not a benefit
  • Tigecycline (Tygacil): general benefit
  • Doxycycline (Apprilon): not a benefit

Tetracycline · DIN 00580929 · 250mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tetracycline · DIN 00580929 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.2680 Health Canada: Marketed since 2011-07-12 · brand TETRACYCLINE · ATC J01AA07 TETRACYCLINE · form Capsule · route Oral · ingredients TETRACYCLINE HYDROCHLORIDE 250 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Tetracycline: Formulary list price $0.0670/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0670 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5293 · Verify on the e-Formulary ↗ (DIN 00580929)

Source record
DIN 00580929: Tetracycline Raw flags: sec3=Y Item: 081224002; group id 34; item number 0070; lccId None; manufacturer id AAP Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0670; ministry $0.0670 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00580929 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5293
Interchangeable products
Tetracyn · DIN 00024422 · not recorded
Shortage status: active shortage (reported 2026-07-28, estimated to end 2026-09-25, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00580929
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Tetracyn · DIN 00024422 · 250mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-26 — choose a marketed DIN from the same-category list.Discontinued 2000-07-26 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-26 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tetracyn · DIN 00024422 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.2680 Health Canada: Cancelled post market since 2000-07-26 · brand TETRACYN CAP 250MG · ATC J01AA07 TETRACYCLINE · form Capsule · route Oral · ingredients TETRACYCLINE HYDROCHLORIDE 250 MG/CAP · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Tetracyn: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=315 · Verify on the e-Formulary ↗ (DIN 00024422)

Source record
DIN 00024422: Tetracyn Raw flags: notABenefit=Y, sec3=Y Item: 081224002; group id 34; item number 0070; lccId None; manufacturer id PFI Source form: Cap; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024422 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=315
Interchangeable products
Tetracycline · DIN 00580929 · $0.0670
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00024422
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2000-07-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:24 Tetracyclines) and how they are covered

Matched class: 08:12:24 Tetracyclines

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: TIGECYCLINE Some products covered without a code (check the product listing): DOXYCYCLINE HYCLATE, MINOCYCLINE HCL 08:12:24 Tetracyclines

DOXYCYCLINE HYCLATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), General benefit (7) · strengths: 20mg, 100mg · Cap, Tab

MINOCYCLINE HCL

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 50mg, 100mg · Cap

TIGECYCLINE

· 1 products · General benefit · strengths: 50mg/Vial · Pd for Inj-5mLVial Pk (Preservative-Free)

DOXYCYCLINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · MR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:24
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CIPROFLOXACIN AND DEXAMETHASONE · Limited Use, codes 509 INDICATIONS AND CLINICAL USE CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of infections caused by most strains of the designated microorganisms in the specific conditions listed below: Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6 months of age due to: Aerobic, Gram-Positive: Streptococcus pneumoniae Staphylococcus aureus Aerobic, Gram-Negative: Haemophilus influenza Moraxella catarrhalis Pseudomonas aeruginosa Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to: Aerobic, Gram-Positive: Staphylococcus aureus Aerobic, Gram-Negative: Pseudomonas aeruginosa To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. PM: https://pdf.hres.ca/dpd_pm/00041611.PDF; date September 27, 2017; DIN 02252716; fetched 2026-09-10 Product monograph CLARITHROMYCIN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) (For additional information on the use of BIAXIN BID® in triple therapy for the treatment of H. pylori infection and active duodenal ulcer recurrence, refer to the Hp-PAC® Product Monograph.) BIAXIN® (clarithromycin for oral suspension USP) Product Monograph Master Template Template Date: September 2020 BIAXIN BID®, BIAXIN® - clarithromycin Page 4 of 107 BIAXIN® is indicated for the treatment of infections due to susceptible organisms, in the following conditions: • Upper Respiratory Tract • Pharyngitis caused by S. pyogenes (Group A ß-hemolytic streptococci). PM: https://pdf.hres.ca/dpd_pm/00078094.PDF; date DEC 17, 2024; DIN 01984853; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following microorganisms: • Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis, agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis). • The following gram-negative organisms: H. ducreyi (chancroid), P. pestis and P. tularensis, B. bacilliformis. Bacteroides, V. comma and K. fetus, and Brucella organisms (in conjunction with streptomycin). • The following gram-negative organisms, when bacteriologic testing indicates appropriate susceptibility to the drug: E. coli, A. aerogenes, Shigella, Mima, Herellea, H. influenzae (respiratory infections), and Klebsiella infections (respiratory and urinary). • The following gram-positive organisms when bacteriologic testing indicates appropriate susceptibility to the drug: anaerobic streptococci, S. pyogenes (for upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the … https://pdf.hres.ca/dpd_pm/00084169.PDF PM date: 2026-03-17 Source product: TETRACYCLINE; DIN 00580929; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Tetracycline · DIN 00580929 Shortage status: active shortage (reported 2026-07-28, estimated to end 2026-09-25, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00580929

Check this DIN again

Other review policies

For Tetracyn: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026